*For medical professionals only for reference
Moms and dads, hurry up and "sweet fragrance" the baby!
Content Summary
On November 23, 2022, a study published in the Journal of the European Society of Dermatology and Venereology showed that early application of emollients or moisturizers is an effective strategy to prevent atopic dermatitis in high-risk infants.
study screenshot
Current status
AD, also known as atopic eczema, is the most common chronic and recurrent inflammatory disease of the skin, affecting 5%-30% of children around the world. Most AD subjects suffer from persistent dryness, itching, eczema, , skin dysbiosis, and epidermal barrier defects. If patients are poorly managed, AD is associated with impaired quality of life (QoL) and increased disease burden, which poses considerable burdens on individuals, families and society. In addition, AD subjects are more likely to suffer from other atopic diseases, including food allergy , asthma and allergic rhinitis . Therefore, it is crucial to clarify the possible mechanisms of AD to develop more precise and effective prevention and treatment strategies.
Conclusion
This meta analysis includes 11 randomized controlled trials , involving 3483 babies. In the included studies, three types of emollients were identified, including cream, emulsion, and blend types.
This study found that:
Early application of emollients can significantly reduce the AD development in high-risk infants;
At the same time, the three emollients, cream type, lotion type and mixed type, are comparable in preventing the development of AD;
However, the results of SUCRA analysis show that emollients may be a better choice to prevent the development of AD in infants;
In addition, the qualitative results show that subjects receiving emollients have more frequent AE.
outlook
In the discussion section of the article, the researcher stated that this study has the following advantages:
This is the first study to investigate the comparative efficacy of different types of emollients through a mesh analysis. This study combines existing indirect evidence to initially determine which type of emollient may be the best treatment for preventing the development of AD in infants;
was included in RCT for counting According to the analysis, this greatly improves the credibility of our findings;
performs subgroup analysis to eliminate the impact of subject status on the combined results;
we identify eligible studies by examining the reference list, which significantly reduces the risk of missing qualified studies if previous meta-analysis (except literature searches in three commonly used electronic databases) significantly reduces the risk of missing qualified studies, and (e) ranking all available emollient types using the results of the SUCRA analysis, which is beneficial to clinical practitioner decision-making.
